
Medibio Completes Oversubscribed Share Purchase Plan Offer

Medibio Limited ("Medibio" ASX:MEB) is pleased to announce the completion of its Share Purchase Plan Offer (**SPP Offer**) previously announced to ASX on 10 July 2019. The Company lodged a Prospectus in relation to the SPP offer on 23 July 2019 followed by a Supplementary Prospectus on 16 August 2019.

The SPP Offer provided eligible shareholders the opportunity to subscribe for up to 121,000,000 of new ordinary shares in the Company at an issue price of \$0.01 (1 cent) per share, subject to scale back at the Company's discretion. The maximum to be raised under the SPP offer was \$1,210,000. Under the terms of the SPP offer one free attaching Option will be issued for each SPP Share successfully subscribed for.

The SPP Offer was heavily supported by eligible shareholders and Medibio received applications of approximately \$1.7 million representing oversubscriptions of 39% (224% based off the original offer size of \$520,000). Consequently, in accordance with the terms and conditions of the SPP Offer, the Company will scale back the allotment of new shares under the SPP Offer to \$1,210,000.

The Company has determined to scale-back the offer on a pro-rata basis for all eligible shareholder acceptances over the minimum acceptance amount of \$1,000.

The Company would like to express its deep appreciation to all eligible shareholders who participated in the SPP Offer and thanks shareholders for this vote of confidence and their continued support.

The new shares and options under the SPP offer will be issued to eligible applicants on Wednesday, 28 August 2019 in accordance with the timetable set out in the Prospectus dated 23 July 2019. Holding statements will be dispatched, and refunds of subscription monies due to the scale back will be made on or around Friday, 30 August 2019.

-Ends-

For more information, please contact:

Mathew Watkins
Company Secretary
+61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.